Several healthcare stocks showed remarkable gains and losses in Friday’s after-market session. Here are the top 12 healthcare stocks that made significant moves.
☝️Learn what media think of AIMD stock.☝️
Check our new FREE NEWS SENTIMENT TOOL.
Gainers:
- Connect Biopharma Hldgs (NASDAQ: CNTB) saw its shares surge by 47.3% to $1.62, with a trading volume of 1.0 million. This volume represented a staggering 2307.1% increase from its average volume over the last 100 days. The company’s market value of outstanding shares now stands at $89.1 million.
- Gelesis Holdings (NYSE: GLS) shares increased by 32.72% to $0.15. The market value of their outstanding shares is $10.7 million.
- Biocept (NASDAQ: BIOC) stock increased by 27.22% to $0.3. The company’s market cap now stands at $5.1 million.
- Clearside Biomedical (NASDAQ: CLSD) stock increased by 21.14% to $1.26. The company’s market cap is now at $77.3 million.
- Regulus Therapeutics (NASDAQ: RGLS) shares increased by 18.39% to $1.03. The company’s market cap is now at $17.3 million.
- Kineta (NASDAQ: KA) stock increased by 16.82% to $3.75. The company’s market cap is now at $31.1 million.
Losers:
- ATI Physical Therapy (NYSE: ATIP) shares fell 19.8% to $0.33 during Friday’s after-market session. The company’s market cap is now at $67.4 million. The company’s Q4 earnings were released yesterday.
- Science 37 Hldgs (NASDAQ: SNCE) stock declined by 18.77% to $0.29. Trading volume for this security closed at 334.3K, accounting for 41.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is $33.8 million.
- Pieris Pharmaceuticals (NASDAQ: PIRS) shares decreased by 13.23% to $1.05. The market value of their outstanding shares is $78.1 million.
- Ainos (NASDAQ: AIMD) stock fell 9.61% to $1.36. The market value of their outstanding shares is $27.1 million.
- Bright Green (NASDAQ: BGXX) shares decreased by 9.59% to $0.86. The company’s market cap is now at $145.8 million.
- Sangamo Therapeutics (NASDAQ: SGMO) shares decreased by 8.96% to $1.83. Sangamo Therapeutics’s trading volume hit 93.1K shares by close, accounting for 6.2% of its average volume over the last 100 days. The market value of their outstanding shares is $308.3 million.
This information benefits investors and helps track the latest trends and movements in the healthcare sector.
AIMD (Ainos, Inc.) Stock Performance
AIMD (Alphatec Holdings, Inc.) is a healthcare technology company specializing in medical specialties. The stock performance on March 17, 2023, as shown by the trading data, has a previous close of $1.56, today’s open at $1.55, and a day’s range of $1.24 to $1.80. The volume for the day is 27,526 shares traded, and the average book over the past three months is 675,057. The market capitalization of AIMD is $13.6 million.
The growth and valuation of AIMD can be analyzed by looking at its earnings growth, revenue growth, P/E ratio, and price-to-sales and price-to-book ratios. Earnings growth for the last year was +3.59%, and no data is available for this year or the next five years. Revenue growth for the previous year was +3,489.71%. The P/E ratio is unavailable, and the price-to-sales and price-to-book ratios are 160.04 and 0.64, respectively.
Compared to its competitors, no data is available for AIMD, according to the available information. The financials for AIMD, including the next reporting date, EPS forecast for the quarter, annual revenue and profit for the last year, and the net profit margin, are also unavailable.
AIMD is categorized as a healthcare technology company that specializes in medical specialties. The company is headquartered in San Diego, California, with no executives to display.
There are no forecasts available for AIMD in the available information. It is essential to note that the lack of data available for AIMD’s financials and competitors makes it challenging to analyze its performance.
The information available on AIMD’s stock performance on March 17, 2023, shows that the stock’s performance was relatively stable. However, further analysis requires more data on the company’s financials and competitors.
AIMD (Ainos, Inc.) Stock Price Overview
Ainos Inc is a technology company, and according to the available information, one analyst has provided a 12-month price forecast for the stock. The median target price estimate is 68.85, a staggering 5,038.33% increase from the last price of 1.34. The high and low estimates for the target price are both 68.85. This forecast suggests that the analyst is optimistic about Ainos Inc’s future performance, and they anticipate a significant increase in the stock price.
The consensus among the polled investment analysts is to outperform the stock of Ainos Inc. This rating has held steady since August and has not changed from an outperform rating. It is essential to note that the investment analysts’ recommendations can impact the stock’s performance and investors’ decisions.
Investors should also pay attention to the stock’s performance over the past few months. Moving the mouse over past months’ details, as indicated by the available information, can provide insights into how the stock has performed recently. Examining the trends can help investors understand whether the stock’s price will continue to rise, fall, or remain stable.
It is crucial to understand that stock price forecasts and analyst recommendations are not guarantees of future performance. While they can be helpful indicators, they are not the only factors influencing a stock’s performance. Economic and political factors, company-specific news, and global events can all impact a stock’s price.
Ainos Inc’s stock price forecast suggests that the analyst is optimistic about the company’s future performance, with a median target price estimate of 68.85, representing a 5,038.33% increase from the last price of 1.34. The consensus among one polled investment analyst is to outperform the stock in Ainos Inc, and this rating has held steady since August. However, investors should consider other factors impacting the stock’s performance and perform due diligence before making investment decisions.